Adaptate and Iontas partner on antibody selection and optimization

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Design Cells)
(Image: Getty/Design Cells)

Related tags: Adaptate, Iontas, Antibody

Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.

Formed recently​ as a spin-out company of GammaDelta Therapeutics, Adaptate’s technology aims to modulate γδ T-cell activity using therapeutic antibodies, with the potential to trigger immune responses against cancer.

Co-funded by Takeda, the spin-out company plans to further develop these antibody targets and advance them into clinical studies.

On its side, Iontas’ platform enables the construction of large libraries of stable cell lines, while at the same time it has the potential to address challenges that occur at early stages of development, according to the company.

The collaborative agreement will see Adaptate work on Iontas’ platform with the aim to select high affinity antibodies based on criteria including function, stability, and expression and transition them through chemistry, manufacturing and controls (CMC) processes.

John McCafferty, Iontas’ CEO commented that the collaboration is a ‘validation’ of the company’s ‘Mammalian Display’ platform, which is expected to facilitate the manufacture of antibody-based therapeutics by reducing the risk of delays and product failure through “detecting and avoiding problematic clones at the outset.”

“Our aim is to ensure the right lead is selected first time, every time,”​ McCafferty noted.

CEO of Adaptate, Natalie Mount, stated that the company anticipates the collaborative work to accelerate entry to the clinic for Adaptate’s oncology candidates.

Related news

Show more

Related products

show more

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

Take the Right Path Upstream with MilliporeSigma | 12-May-2020 | Technical / White Paper

The first commercial monoclonal antibody (mAb) was approved in 1986 and today, the global market is large and growing. Reports estimate the size of the...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Related suppliers

Follow us

Products

View more

Webinars